Abstract
BackgroundDespite much effort on the treatment of breast cancer over the decades, a great uncertainty regarding the appropriate molecular biomarkers and optimal therapeutic strategy still exists. This research was performed to analyze the association of SPAG5 gene expression with clinicopathological factors and survival outcomes.MethodsWe used a breast cancer database including 5667 patients with a mean follow-up of 69 months. Kaplan-Meier survival analyses for relapse free survival (RFS), overall survival (OS), and distant metastasis-free survival (DMFS) were performed. In addition, ROC analysis was performed to validate SPAG5 as a prognostic candidate gene.ResultsMean SPAG5 expression value was significantly higher with some clinicopathological factors that resulted in tumor promotion and progression, including poor differentiated type, HER2 positive or TP53 mutated breast cancer. Based on ROC-analysis SPAG 5 is a suitable prognostic marker of poor survival. In patients who received chemotherapy alone, SPAG5 had only a moderate and not significant predictive impact on survival outcomes. However, in hormonal therapy, high SPAG5 expression could strongly predict prognosis with detrimental RFS (HR = 1.57, 95% CI 1.2–2.06, p = 0.001), OS (HR = 2, 95% CI 1.05–3.8, p = 0.03) and DMFS (HR = 2.36, 95% CI 1.57–3.54, p < 0.001), respectively. In addition, SPAG5 could only serve as a survival predictor in ER+, but not ER- breast cancer patients. Patients might also be at an increased risk of relapse despite being diagnosed with a lower grade cancer (well differentiated type).ConclusionsSPAG5 could be used as an independent prognostic and predictive biomarker that might have clinical utility, especially in ER+ breast cancer patients who received hormonal therapy.
Highlights
Despite much effort on the treatment of breast cancer over the decades, a great uncertainty regarding the appropriate molecular biomarkers and optimal therapeutic strategy still exists
Mean Sperm-associated antigen 5 (SPAG5) expression value was higher in estrogen receptor (ER)- than ER+ breast cancer patients, similar trend was observed in progesterone receptor (PR)- and Epidermal growth factor receptor 2 (HER2)+ breast cancer patients
The results showed that higher expression of SPAG5 was associated with worse relapse free survival (RFS) (n = 3557, hazard ratio (HR) = 1.72, 95% Confidence Interval (CI) 1.54–1.94, p < 0.001), overall survival (OS) (n = 1117, HR = 1.86, 95% CI 1.46–2.37, p < 0.001), and distant metastasis-free survival (DMFS) (n = 1610, HR = 1.88, 95% CI 1.53–2.32, p < 0.001) in patients with breast cancer
Summary
Despite much effort on the treatment of breast cancer over the decades, a great uncertainty regarding the appropriate molecular biomarkers and optimal therapeutic strategy still exists. Despite much effort on the treatment of breast cancer over the decades, a great uncertainty regarding the optimal therapeutic strategy, especially effective precision medicine for breast cancer still exists [2]. As only those individuals who harbor the appropriate molecular biomarkers are eligible for. Knockdown of SPAG5 could significantly suppress proliferation and invasion of prostate cancer cells in vitro, along with inhibiting the growth and metastasis of tumor in vivo [10]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
